Fibrocell Science (FCSC) Getting Somewhat Positive News Coverage, Analysis Shows
Press coverage about Fibrocell Science (NASDAQ:FCSC) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fibrocell Science earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.0463352878769 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Exton biotech expects to raise $10.5 million in a public offering of its stock (philly.com)
- Fibrocell Science Inc (FCSC) Feels the Heat of Share Dilution – Smarter Analyst (smarteranalyst.com)
- Fibrocell Science, Inc. (FCSC) Infectious to Cheers up Sector on Leading Facts – Stock News Stop (stockmarketstop.com)
- Should You Worry About Fibrocell Science Inc’s (FCSC) CEO Pay Check? (finance.yahoo.com)
- Up to Date Stock in scrutiny: Fibrocell Science, Inc. (NASDAQ:FCSC) – Market Breaking Point (press release) (journalfinance.net)
Shares of Fibrocell Science (NASDAQ FCSC) traded up $0.02 during midday trading on Friday, hitting $0.70. 520,545 shares of the company’s stock traded hands, compared to its average volume of 391,074. Fibrocell Science has a 52 week low of $0.67 and a 52 week high of $4.64.
A number of research firms recently weighed in on FCSC. Zacks Investment Research upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $7.60 price objective on shares of Fibrocell Science in a research report on Thursday, October 5th. Canaccord Genuity restated a “buy” rating and set a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. Finally, ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Fibrocell Science currently has an average rating of “Hold” and a consensus price target of $5.21.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.